FDA definition of non-accurately and reliably [Bioanalytics]

posted by jag009  – NJ, 2013-01-09 23:20 (4522 d 00:02 ago) – Posting: # 9808
Views: 9,140

Hi everyone,

Can someone clarify this for me... When a FDA draft guidance says bioequivalence is based on the prodrug unless "it is not possible to measure in plasma accurately and reliably", what does it really mean? Does it mean the LoQ has to be low enough? What about the overall variability of the concentration values?

The reason I ask is because I have a prodrug with highly variable concentration values. At the dose I studied in a pilot involving only the reference product, 8-9 out of 24 subjects had almost all BLQs in their entire PK profiles. For these 8-9 subjects, their detectable concentration values are not much higher than the LoQ value). The rest of the subjects are ok with only BLQ values in the last 6 timepoints (24 total). The prodrug is poorly water soluble.

The pivotal study will be dose at 2 x my pilot dose. Assuming linear kinetics and the resulting concentration will be doubled.

Thanks
John

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
69 visitors (0 registered, 69 guests [including 14 identified bots]).
Forum time: 00:23 CEST (Europe/Vienna)

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5